Biogen Stock - RayThera acquisition expands Alzheimer’s pipeline

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 17:18 CET. Details in the imprint.

Biogen Inc. (US09062X1037) is in the headlines after announcing a definitive agreement to acquire privately held RayThera in a deal valued at up to $1 billion. The transaction is intended to bolster Biogen’s Alzheimer’s disease pipeline, according to a recent MarketBeat summary of the company’s disclosure.

RayThera deal adds to Alzheimer’s push

According to a recent MarketBeat news item, Biogen agreed to acquire RayThera for total consideration of up to $1 billion, tying milestone payments to development and commercial progress. The report notes that RayThera focuses on therapies in Alzheimer’s disease and related neurodegenerative conditions.

The structure of the deal, as summarized in that coverage, combines upfront and potential milestone payments, a typical approach in biotech M&A where late-stage clinical risk remains significant. With this transaction, Biogen seeks to broaden its Alzheimer’s portfolio beyond existing assets such as Leqembi, co-developed with Eisai.

Long-term strategy and pipeline positioning

The RayThera agreement fits into Biogen’s long-term strategy of concentrating capital on neurology and specialty immunology while pruning non-core assets. Management has repeatedly emphasized a focus on diseases with high unmet medical need, including Alzheimer’s, multiple sclerosis and rare neuromuscular conditions.

Recent valuation work cited by Yahoo Finance suggests that Biogen’s stock could be modestly undervalued on the strength of its pipeline, with a fair value estimate of around $219 per share versus a recent close near $196.58. That analysis highlights both pipeline optionality and execution risk in neurology.

How Biogen makes its money

Biogen generates most of its revenue from therapies targeting neurological disorders, including multiple sclerosis treatments such as Tecfidera and Tysabri, the spinal muscular atrophy drug Spinraza, and Alzheimer’s therapy Leqembi, alongside biosimilars and other specialty medicines. These products underpin cash flow to fund acquisitions like RayThera.

Where the stock trades today

Biogen stock (US09062X1037) trades on the Nasdaq at $196.58 as of 06/18/2026, 16:00 Eastern Time.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.